Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2909 - Bidirectional chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with pressurized intraperitoneal aerosol chemotherapy (PIPAC): results of 103 procedures in 52 patients

Date

09 Sep 2017

Session

Poster display session

Presenters

Vladimir Khomyakov

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

V. Khomyakov1, A. Ryabov2, L. Bolotina3, A. Utkina1, A. Ivanov1, O. Kuznetsova4

Author affiliations

  • 1 Thoracoabdominal, P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Radiological Center, 125284 - Moscow/RU
  • 2 Thoracoabdominal, P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Radiological Center, Moscow/RU
  • 3 Chemotherapy, P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Radiological Center, 125284 - Moscow/RU
  • 4 Pathology, P.A. Herzen Moscow Research Oncological Institute – branch of the National Medical Research Radiological Center, 125284 - Moscow/RU
More

Resources

Abstract 2909

Background

Up to 43% of GC patients show synchronous PC at time of diagnosis and peritoneal relapse develops in 10–46% of cases after radical surgery. Systemic chemotherapy shows low response rate (14-25%) and median survival of 8-10 months. Innovative therapeutic approaches are needed to improve survival.

Methods

Treatment protocol for untreated patients included initial staging laparoscopy/laparotomy, 3–4 courses of systemic chemotherapy (XELOX) followed by Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) with low-dose Cisplatin and Doxorubicin every 6 weeks until progression of disease or death. Criteria of progression were 50% and more PCI increase or distant metastases. Patients with primary or recurrent GC, who received earlier one or two lines of systemic chemotherapy, didn’t receive 4 XELOX courses before PIPAC. Primary endpoints were overall survival and pathologic response after peritoneal rebiopsy.

Results

52 patients were included (15 men, 37 women, mean age 53.5 years), 38 patients had primary GC with PM and 14 had peritoneal relapse after surgery (with or without adjuvant therapy). 19 patients had systemic chemotherapy before inclusion to the program. Mean PCI was 12.6 (min-max 3-34). Altogether, 103 PIPAC procedures were performed in the 52 patients. The main reason for not undergoing more than one PIPAC was PC progression (16). Pathological response was estimated in 30 pts underwent more than 1 PIPAC. 33% of patients showed complete pathologic response (CR), 50% - PR and 17% of cases had weak or no response. PCI score has decreased in 37% of patients, remained stable in 10% and has increased in 53% of cases. Thus PCI change isn't equal to the pathologic response. Median survival was 14.6 months and one-year overall survival was 62%. The median survival was better in patients with low PCI and in those who responded to systemic chemotherapy, but the difference was not significant.

Conclusions

Bidirectional chemotherapy combining intravenous chemotherapy and PIPAC can induce objective tumor regression and is associated with a promising survival in GC with PC.

Clinical trial identification

Legal entity responsible for the study

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russian Federation

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.